CN113862368A - Primer composition and kit related to gene detection of tumor chemotherapy drugs - Google Patents
Primer composition and kit related to gene detection of tumor chemotherapy drugs Download PDFInfo
- Publication number
- CN113862368A CN113862368A CN202111363558.2A CN202111363558A CN113862368A CN 113862368 A CN113862368 A CN 113862368A CN 202111363558 A CN202111363558 A CN 202111363558A CN 113862368 A CN113862368 A CN 113862368A
- Authority
- CN
- China
- Prior art keywords
- primer
- artificial sequence
- kit
- tumor
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a tumor chemotherapy drug gene detection primer composition, a kit and a detection method thereof, the kit aims at tumor chemotherapy drug individualized genes and comprises ABCB1, ATIC, CBR3, CDA, DPYD, ERCC1, GSTP1, MTHFR, MTRR, NQO1, SOD2, TP53, UGT1A1, UMPS, XPC and XRCC1, 22 pairs of primers or a combination containing part of the primers, and a forward primer and a reverse primer of each pair of primers comprise an amplification primer pair and other sequences connected with the 5' end of the amplification primer pair. The specific sequences of the forward primer and the reverse primer of each pair of primers are selected from the sequences shown in SEQ ID NO.1-44, and a kit for detecting the individualized genes of the tumor chemotherapeutic drugs is provided. The kit and the specific primer group can quickly, accurately and once detect the individual mutation gene hot spot area of the tumor chemotherapeutic drug, can detect samples such as blood and the like, and can be well used for guiding chemotherapeutic drugs and selecting chemotherapeutic schemes.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a primer composition and a kit related to gene detection of tumor chemotherapy drugs.
Background
The drug effect has individual differences, and the influencing factors comprise physiological factors, pathological factors, environmental factors and genetic factors, wherein the genetic factors mainly depend on individual gene polymorphism, including single nucleotide polymorphism and copy number polymorphism, and the polymorphism can influence pharmacokinetics and pharmacodynamics through drug metabolic enzyme, drug transport protein, drug receptor, pathogenic gene and the like, so that the individual differences of the drug curative effect and toxicity are caused.
Chemotherapy is a common means for tumor treatment, but chemotherapy patients still have the condition of poor chemotherapy effect or large toxic and side effect, and patients who relapse or transfer after tumor treatment also have the condition that the original chemotherapy scheme is invalid.
Next-Generation Sequencing (NGS), also called second-Generation Sequencing, is a high-throughput detection technique that can sequence hundreds of thousands or even hundreds of millions of DNA molecules at a time, which has been developed in recent years, and is now widely used in the fields of prenatal detection, tumor mutation analysis and medication guidance, pathogen microorganism screening, and the like. The Illumina platform is the most common NGS sequencer in China at present, and has higher market share. Domestic MGI platforms also each have unique advantages, and domestic application rates are also steadily increasing.
Prior to NGS sequencing, it is often necessary to enrich and amplify specific regions of sample DNA, a process known as library construction. The multiplex PCR technology does not need to preprocess the sample, a small amount of sample or a sample degraded to a certain degree can be used, and the multiplex PCR technology is suitable for most clinical conditions; meanwhile, the library building process is simple, can be completed within hours, and has low overall cost. However, the multiplex PCR technology puts higher requirements on the design of an amplification primer pool, and a large amount of primer dimers are easily generated by slight errors, so that target fragments are sharply reduced, or the operation of tube division is forced, thereby weakening the original advantages.
Disclosure of Invention
The invention aims to provide a tumor chemotherapeutic drug individualized gene, which comprises ABCB1, ATIC, CBR3, CDA, DPYD, ERCC1, GSTP1, MTHFR, MTRR, NQO1, SOD2, TP53, UGT1A1, UMPS, XPC and XRCC1, and comprises 22 pairs of primers or a combination comprising a part of primers, wherein a forward primer and a reverse primer of each pair of primers comprise an amplification primer pair and other sequences connected with the 5' end of the amplification primer pair. The structure of each primer in the primer composition of the invention is schematically shown in FIG. 1.
The invention provides a kit for detecting tumor chemotherapeutic drug genes, which comprises specific primers of the tumor chemotherapeutic drug genes, DNA polymerase, PCR buffer solution, dNTP and the like. The composition of the kit is detailed in table 1.
TABLE 1 kit composition
| Composition of | Principal Components | Quantity (12) | Volume of |
| Amplification reaction solution 1 | DNA polymerase, dNTPs, buffer | 1 tube | 150μL |
| Amplification reaction solution 2 | DNA polymerase, dNTPs, buffer | 1 tube | 360μL |
| Primer combination | Primer and method for producing the same | 1 tube | 60μL |
| Joint A | Aqueous solution containing universal primer | 4 tubes | 12 mu L/tube |
| Joint B | Aqueous solution containing universal primer | 3 tube | 16 mu L/tube |
The invention also provides a kit for detecting the individualized genes of the tumor chemotherapy drugs, which comprises at least one pair of two pairs of linkers, wherein the two pairs of linkers respectively correspond to two sequencing platforms, namely Illumina and MGI, and DNA fragments matched with the sequence shown in SEQ ID NO.45 or the sequence shown in SEQ ID NO.46 are contained in the linkers.
The method is simple, is convenient to operate, can complete the construction of the NGS library within hours, and has low overall cost. The invention is helpful to realize the conversion of the reagent from laboratory to clinical application and in-vitro diagnosis reagent, and has good application prospect
Drawings
FIG. 1 is a schematic diagram of the structure of each primer in the primer composition of the present invention.
Detailed Description
The primer composition of the tumor chemotherapeutic drug gene of this example 1 is specifically shown in table 2:
TABLE 2
The kit for detecting the individualized genes of the tumor chemotherapeutic drugs specifically amplifies a plurality of genes related to the tumor chemotherapeutic drugs in a DNA sample of a tumor patient by a multiplex PCR method, and mainly comprises the following steps:
1. sample preparation
The applicable range of the sample comprises samples such as whole blood, plasma, serum and the like. Samples such as whole blood, plasma, serum and the like were extracted from genomic DNA using a Qiagen tissue DNA extraction kit, and the specific procedures were as specified in the kit procedures. Each time, 200. mu.L of whole blood is extracted, and the blood plasma and blood serum are not less than 800. mu.L. The extracted DNA was dissolved in Tris-HCl (10mmol/L, pH 8.0), the mass extracted was measured by UV spectrophotometer and the concentration was determined. The kit recommends that the accounting quantity adopted by each reaction is 20ng-50 ng.
2. Library construction
2.1 first round PCR reaction
Gene-specific PCR reactions were prepared as shown in Table 3 below, and the corresponding DNA samples were added to each tube.
TABLE 3
The PCR reaction was run according to the procedure of Table 4 below.
TABLE 4
2.2 first round PCR product purification
2.2.1 the tubes were removed from the PCR machine and centrifuged quickly to spin the liquid to the bottom of the tube.
2.2.2 adding 1.2 times volume of purified magnetic beads into each tube, shaking and mixing evenly and centrifuging quickly. The mixture was allowed to stand at room temperature for 5 minutes.
2.2.3 transfer each tube to a magnetic rack and stand at room temperature for 5 minutes or until the liquid is clear. The supernatant was carefully aspirated, taking care to avoid hitting the beads.
2.2.4 Add 150. mu.L 70% ethanol per tube wash, incubate for 30 seconds and aspirate the ethanol, taking care to avoid touching the beads. The washing was repeated once.
2.2.5 cover the tube, place each tube on the magnetic rack after rapid centrifugation, carefully suck the remaining ethanol in the tube. 2.2.6 at room temperature for 2-3 minutes until the beads are dry. Add 64. mu.L of ribozyme-free water to each tube, cover the tube, shake and mix well and centrifuge quickly.
2.2.7 transfer each tube to a magnetic rack and allow to stand at room temperature for 5 minutes. Transfer supernatant to a new tube.
2.3 second round PCR reaction
The adaptor-added PCR reaction solution was prepared as shown in Table 5 below.
TABLE 5
The PCR reaction was run according to the procedure of Table 6 below.
TABLE 6
2.4 library purification and quality control
2.4.1 the tubes were removed from the PCR machine and centrifuged quickly to spin the liquid to the bottom of the tube.
2.4.2 adding 1 time volume of purified magnetic beads into each tube, shaking and mixing evenly and quickly centrifuging. The mixture was allowed to stand at room temperature for 5 minutes.
2.4.3 transfer each tube to a magnetic rack and stand at room temperature for 5 minutes or until the liquid is clear. The supernatant was carefully aspirated, taking care to avoid hitting the beads.
2.4.4 Add 150. mu.L 70% ethanol per tube wash, incubate for 30 seconds and aspirate the ethanol, taking care to avoid touching the beads. The washing was repeated once.
2.4.5 cover the tube, place each tube on the magnetic rack after rapid centrifugation, carefully suck the remaining ethanol in the tube. 2.4.6 at room temperature for 2-3 minutes until the beads are dry. Add 32. mu.L of ribozyme-free water to each tube, cover the tube, shake and mix well and centrifuge quickly.
2.4.7 the tubes were transferred to a magnetic rack and allowed to stand at room temperature for 5 minutes. Transfer supernatant to a new tube.
2.4.8 quantification of the library using Qubit; the library fragments were analyzed for size and purity using Qseq 100.
3. Sequencing on machine
3.1 Each library was diluted to 5nM in aliquots and mixed in small aliquots.
3.2 denaturation by addition of an equal volume of 0.2N NaOH and dilution to 15pM with HT1 solution.
3.3 Take 594. mu.L of the 15pM mixed library and add 6. mu.L of 12.5pM PhiX library control.
3.4 add 600 μ L of the above sample to the sequencing kit provided by the invention, load into illumina miseq sequencer for sequencing.
The above examples are merely illustrative for clearly illustrating the present invention and are not intended to limit the embodiments of the present invention. The scientific and technical terms used in this patent have the same meaning as understood by one of ordinary skill in the art.
Sequence listing
<110> bud
<120> primer composition and kit related to gene detection of tumor chemotherapy drugs
<130> 20211116
<141> 2021-11-17
<160> 47
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
tgctcccagg ctgtttattt ga 22
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
agcccatcct gtttgactgc 20
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tgcgtgccta acaaaatgct 20
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
agtagcaggg gttgactggt 20
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
gacaggattc tggtgaatgc g 21
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
tccgaagcag acgtttacca 20
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gaagcctgag tgtgtccagc 20
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
gggtgcccac ctttaccttt 20
<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
cccagcacca aaaagagcaa tc 22
<210> 10
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
atgacaattg atttccccgt aggta 25
<210> 11
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
aattccagca ggattcttac ctg 23
<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
aagcactgca gtaccttgga a 21
<210> 13
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
agagaaagtt ttggtgaggg ca 22
<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
agtgtagaaa tggccggatt ga 22
<210> 15
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
ttcaccaact tatgccaatt ctct 24
<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
catcagtgag aaaacggctg c 21
<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
cagagacagt gccccaagag 20
<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
tgggcacctt cagctttctt 20
<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
agagctcacc tgaggaacag 20
<210> 20
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
ccctattgat ggcttctgcc c 21
<210> 21
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
ggtggacatg gtgaatgacg g 21
<210> 22
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
acaagaagcc cctttctttg tt 22
<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 23
aagtgatgcc catgtcggtg 20
<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
ctgtcatccc tattggcagg t 21
<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 25
cactccagca tcactcactt tg 22
<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
ctacctgaag agcaagtccc c 21
<210> 27
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 27
tgccttgaag tgatgaggag g 21
<210> 28
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
aacggctcta accttatcgg a 21
<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 29
ccaggcgttt cttccatcct 20
<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 30
tggttgactt acctctctgt gc 22
<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 31
gatctgcgcg ttgatgtgag 20
<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 32
gggctgtgct ttctcgtctt 20
<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 33
agctgccctg gtaggttttc 20
<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 34
tcactgaaga cccaggtcca 20
<210> 35
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 35
tctgaaagtg aactccctgc tac 23
<210> 36
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 36
cctttgctcc tgccagaggt t 21
<210> 37
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 37
catgcttggg gccatccag 19
<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 38
tcctcccttt ggaatggcac 20
<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 39
tggagattct cgagcagcag 20
<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 40
atgcaactgg gtggatcctg 20
<210> 41
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 41
caggtgtggg gcctgtagt 19
<210> 42
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 42
agtctgactc ccctccagat tc 22
<210> 43
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 43
agtctgactc ccctccagat tc 22
<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 44
gtgcgtaagg agtgggtgct 20
<210> 45
<211> 34
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 45
gtgactggag ttcagacgtg tgctcttccg atct 34
<210> 46
<211> 33
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 46
tcgtcggcag cgtcagatgt gtataagaga cag 33
<210> 47
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 47
tgctcccagg ctgtttattt ga 22
Claims (9)
1. A tumor chemotherapy drug gene detection primer composition is characterized in that: the primer set comprises 22 pairs of primers or a combination containing a part of the primers, wherein a forward primer and a reverse primer of each pair of primers comprise an amplification primer pair and other sequences connected with the 5' ends of the amplification primer pair. The specific sequence of the forward primer and the reverse primer of each pair of primers is selected from the sequences shown in SEQ ID NO. 1-44.
2. The primer composition for gene detection of tumor chemotherapeutic drugs according to claim 1, wherein: the specific sequence of the forward primer and the reverse primer of each pair of primers is 18-25 base sequences in the sequence.
3. The primer composition for gene detection of tumor chemotherapeutic drugs according to claim 1, wherein: the forward primer of the amplification primer pair comprises 20-35 base sequences in the sequence shown in SEQ ID NO. 45.
4. The primer composition for gene detection of tumor chemotherapeutic drugs according to claim 1, wherein: the reverse primer of the amplification primer pair comprises 20-35 base sequences in the sequence shown in SEQ ID NO. 46.
5. A kit for gene detection of tumor chemotherapy drugs is characterized in that: comprising the primer composition of any one of claims 1-4.
6. The kit for gene detection of tumor chemotherapeutic drugs according to claim 5, wherein: including DNA polymerase, PCR buffer, dNTP and ultrapure water.
7. The kit for gene detection of tumor chemotherapeutic drugs according to claim 5, wherein: comprises at least one of two pairs of adaptors corresponding to the two sequencing platforms Illumina and MGI respectively, wherein the adaptor internally contains a DNA fragment matched with the sequence of any one of claims 3 or 4.
8. The use of the kit according to claim 5 or 6 for the genetic testing of tumor chemotherapeutic drugs, wherein: the kit is suitable for the molecular detection of peripheral blood DNA.
9. Use of the kit according to claim 5 or 6 for the detection of genes related to chemotherapeutic drugs for tumors based on the NGS method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111363558.2A CN113862368A (en) | 2021-11-17 | 2021-11-17 | Primer composition and kit related to gene detection of tumor chemotherapy drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111363558.2A CN113862368A (en) | 2021-11-17 | 2021-11-17 | Primer composition and kit related to gene detection of tumor chemotherapy drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113862368A true CN113862368A (en) | 2021-12-31 |
Family
ID=78984745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111363558.2A Withdrawn CN113862368A (en) | 2021-11-17 | 2021-11-17 | Primer composition and kit related to gene detection of tumor chemotherapy drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113862368A (en) |
-
2021
- 2021-11-17 CN CN202111363558.2A patent/CN113862368A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110964826B (en) | Colorectal cancer suppressing gene methylation high-throughput detection kit and application thereof | |
| CN107955832B (en) | Primer set and method for simultaneously detecting thalassemia, deafness, phenylketonuria and hepatolenticular degeneration disease | |
| CN110218781B (en) | Composite amplification system of 21 micro haplotype sites, next generation sequencing and typing kit and typing method | |
| CN106498036A (en) | A kind of construction method in the Drug Discovery SNP variations library for high-flux sequence detection and its application | |
| CN106498035A (en) | A kind of construction method and its application for detecting chemotherapeutics gene SNP variation library for high-flux sequence | |
| CN111073961A (en) | High-throughput detection method for gene rare mutation | |
| CN113025701B (en) | Early screening method and kit for non-alcoholic fatty liver disease susceptibility gene | |
| CN111647654A (en) | Primer composition, kit and method for detecting hemochromatosis and hepatolenticular degeneration susceptibility gene mutation | |
| CN111808944A (en) | Gene detection method for children personalized medicine | |
| CN110541033A (en) | composition for detecting EGFR gene mutation and detection method | |
| CN113278611A (en) | Capture sequencing probes and uses thereof | |
| WO2015196752A1 (en) | A method and a kit for quickly constructing a plasma dna sequencing library | |
| CN110846408A (en) | Primer combination for detecting TTN gene mutation and application thereof | |
| CN112280849B (en) | Composite amplification system and kit for anti-depression individualized medication genotyping detection | |
| Sridhar et al. | Molecular genetic testing methodologies in hematopoietic diseases: current and future methods | |
| CN111748628B (en) | Primer and kit for detecting thyroid cancer prognosis related gene variation | |
| CN113840923A (en) | Methods, systems, and devices for nucleic acid detection | |
| Alcaide et al. | Ultrasensitive detection of circulating tumor DNA in lymphoma via targeted hybridization capture and deep sequencing of barcoded libraries | |
| CN113862368A (en) | Primer composition and kit related to gene detection of tumor chemotherapy drugs | |
| CN113025702B (en) | Early screening method and kit for ankylosing spondylitis susceptibility genes | |
| CN115418394A (en) | Composition, kit and method for detecting CHO cell genome DNA | |
| CN112266963B (en) | Detection kit for combined detection of chronic granulocytic leukemia | |
| CN112501283A (en) | Guiding method and kit for carbamazepine personalized medicine gene | |
| CN112553325A (en) | Guiding method and kit for sufentanil personalized medicine gene | |
| CN112592972A (en) | Early screening method and kit for diffuse toxic goiter susceptibility genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20211231 |